WHO flags funding gaps in prevention, treatment of TB

1. At a Glance

• The WHO Global Tuberculosis Report, 2026 finds that 86% of TB spending in 2025 came from domestic sources. Over the same year, international donor funding fell by 14%, from $1.1 billion (2024) to $0.94 billion (2025) [1].
• $22 billion a year is needed for TB prevention, diagnosis, treatment and care to meet the targets agreed at the 2023 UN High-Level Meeting (UNHLM) on TB, which are due by 2027. Actual funding falls far short of this [1].
• India matters here for three reasons. It is one of the BRICS countries that together supply 65% of domestic TB funding in LMICs. It lies in the WHO South-East Asia Region, which had the most new TB cases in 2025 (35%). And it runs its own TB Mukt Bharat elimination drive [1][5].
• For UPSC this links GS-II (health, international institutions) with GS-III (S&T, financing for development). It also connects to SDG 3.3 and to the risk of depending on donors for global health.

2. Why in the News

• Nov 2026: WHO released the Global Tuberculosis Report, 2026. It records the first full-year measurement of the 2025 cuts in international donor funding [1].
• WHO's 2025 report had said it was "too early" to assess 2025 funding reliably. It said that data would be gathered in the 2026 round of global TB data collection [3]. The 2026 report is the result of that round.
• WHO also called on countries in the South-East Asia Region to speed up TB action (reported on 14 Nov 2026) [1].

3. Background & Evolution

• Global TB Report: WHO publishes it every year. It tracks the disease burden, funding, and progress towards the End TB / UNHLM targets [2][4].
• Milestones:
• 2015–2024: International donor funding for TB stayed fairly flat at $1.1–1.3 billion a year [1].
• 2023: The UN High-Level Meeting on TB set global targets to be met by 2027 [1].
• Nov 2024: The Global TB Report 2024 recorded a 17.7% fall in India's TB incidence (2015–2023), against a global fall of 8.3% [6].
• July 2025: The Global Fund's 2024–2026 grant cycle was cut by US$1.4 billion (11% of the original allocation) [3].
• 12 Nov 2025: The Global TB Report 2025 was released. It estimated that 10.7 million people fell ill with TB and that TB caused over 1.2 million deaths [2].

• Nov 2026: The Global TB Report 2026 quantified the funding fall for 2025 [1].

• Related initiatives (general knowledge, not in the retrieved sources; verify before use): WHO End TB Strategy (adopted 2014; 2016–2035); SDG 3.3 (end the TB epidemic by 2030); India's TB elimination target of 2025; and the National TB Elimination Programme (NTEP) under MoHFW.

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic

• The $22 bn/yr need is set against domestic funding of $5.63 bn plus donor funding of $0.94 bn in LMICs. That is a gap of more than three times the available money (derived from the [1] figures).
• Money is concentrated: the five BRICS countries account for 65% of LMIC domestic TB funding. Low-income countries outside BRICS remain dependent on donors [1][3].
• WHO says progress has been "constrained by the overall level of investment" [1].

Geopolitical / Strategic

• The 2025 cuts by donors, along with the $1.4 bn cut to the Global Fund, show how exposed global health is to the budget priorities of donor countries [3].
• BRICS countries funding their own TB response strengthens their health sovereignty. India could use this to play a leading role on health in the Global South.

Social

• More than 80% of TB cases and deaths occur in LMICs. TB is a disease of poverty, closely linked to undernutrition, crowded housing and catastrophic health spending [1].
• Cuts to donor-funded services hit case-finding and treatment for marginalised groups in fragile states hardest [3].

Scientific / Technological

• Research funding ($1.2 bn) is less than a quarter of the $5 bn target. This slows new vaccines, shorter treatment regimens and point-of-care diagnostics [1].

Governance / Administrative

• WHO says that after the 2025 donor cuts, political commitment and domestic funding in high-burden countries are "more important than ever" [3].
• India's reported 21% fall in incidence, against a global fall of 12%, is offered as evidence of what domestically led programmes can achieve. The 21% comes from the official release [5]; the 12% global figure comes from the same search results but was not checked against the WHO report. Fiscal federalism matters because health is a State subject.

6. Recent Developments (last 12–18 months)

• July 2025: The Global Fund's 2024–26 allocation was cut by US$1.4 bn (11%) [3].
• 12 Nov 2025: Global TB Report 2025 released: 10.7 mn people fell ill and >1.2 mn died; WHO warned that global gains are endangered by funding problems [2].
• 12 Dec 2025: The Health Ministry (via PIB) cited the WHO report: India's TB incidence fell 21%, from 237 to 187 per lakh (2015–2024) [5].
• 2026: WHO's data-collection round focused on monitoring the impact of donor cuts [3].
• Nov 2026: Global TB Report 2026: 86% of TB spending domestic; donor funding −14% to $0.94 bn; South-East Asia Region had 35% of new cases [1].

7. Prelims Hooks

• The Global Tuberculosis Report is published by the WHO, not by the Stop TB Partnership or the Global Fund [1].
• Per the 2026 report, ~86% of TB spending in 2025 came from domestic sources [1].
• International donor funding for TB fell 14%, from $1.1 bn (2024) to $0.94 bn (2025) [1].
• Donor funding for TB held at $1.1–1.3 bn/yr from 2015 to 2024 [1].
• $22 bn/yr is needed to meet the targets of the 2023 UN High-Level Meeting on TB by 2027 [1].
• Brazil, China, India, Russia and South Africa provided $3.7 bn (65%) of the $5.63 bn domestic TB funding in LMICs [1].
• TB research funding was $1.2 bn in 2023, against a target of $5 bn/yr [1].
• The WHO South-East Asia Region had the largest share of new TB cases in 2025: 35% [1].
• More than 80% of TB cases and deaths are in low- and middle-income countries [1].
• The Global Fund's 2024–26 grant cycle was cut by US$1.4 bn (11%) as of July 2025 [3].
• Global TB Report 2025: 10.7 million fell ill with TB in 2024; >1.2 million deaths [2].
• India's TB incidence: 237 → 187 per lakh (2015–2024), a 21% fall (per the WHO 2025 report as cited by MoHFW) [5].
• Global TB Report 2024: India's incidence fell 17.7% (2015–23), against 8.3% globally [6].

8. Why '86% Domestic' Is Not Fully Good News

• The share went up partly because donor money went down
• 86% domestic sounds like countries are standing on their own feet [1].
• But a share is a fraction. When donor money fell 14% to $0.94 bn, the domestic share would rise even if no country spent one rupee more [1].

• So read the 86% together with the total. Domestic ($5.63 bn) plus donor ($0.94 bn) is about $6.6 bn. That is only about 30% of the $22 bn needed each year (worked out from [1]).

• Five countries hide everyone else in the average

• BRICS gave $3.7 bn of the $5.63 bn domestic money. That leaves only about $1.9 bn for all the other LMICs (low- and middle-income countries) together (worked out from [1]).
• Brazil, China and Russia already pay 100% of their own TB costs [3]. So donor money matters most to the poorer countries outside BRICS.

• For these countries, the $0.94 bn from donors is close to one-third of all their TB money. A 14% cut hurts them much more than the global figure suggests (estimate from [1][3]).

• The donor cut came on top of ten flat years

• Donor money stayed at $1.1–1.3 bn a year from 2015 to 2024 [1].
• Prices of staff, drugs and tests rose over those years. So flat money already bought less each year. The 2025 cut is a real fall on top of that.

9. Free Treatment Still Leaves Families Poorer

• Government spending is not the same as the patient paying nothing
• The report counts money spent on TB programmes. It does not count what the family loses.
• WHO counts three kinds of cost: medical bills, other costs like travel and food, and lost wages [9].

• A cost is called catastrophic when it is more than 20% of a household's yearly income or spending [9].

• Most families in many countries still face that level of cost

• In national surveys (2015–2024), the share of TB families facing catastrophic costs ranged from 13% in El Salvador to 92% in the Solomon Islands [9].

• For drug-resistant TB, the average was 82% across 31 countries [9]. These patients need longer treatment, so they lose more work days.

• Why this matters for the funding debate

• The End TB Strategy aims for zero TB families facing catastrophic costs [9].
• Donor cuts mostly hit services, so families have to pay or travel more for the same care. This pushes catastrophic costs up, not down.
• When you write about money, ask two questions: how much did governments spend, and how much did families lose?

10. Food Is the Cheapest Gap to Close

• Indian research shows food works almost like a medicine
• The RATIONS trial in Jharkhand, funded by ICMR, gave monthly food rations to the families of TB patients [10].
• TB among these family members fell by nearly half [10].

• A 2025 modelling study found that giving a simple food basket to half of India's TB patients and their families could prevent about 3.6 lakh deaths and 8.8 lakh cases between 2023 and 2035 [11].

• India has acted, but only partly

• In October 2024 the Centre raised Ni-kshay Poshan Yojana support from ₹500 to ₹1,000 a month, paid by DBT (direct benefit transfer, money sent straight to the bank account) [12].

• It approved an extra ₹1,040 crore for this. It also planned extra high-energy food for patients with a BMI below 18.5 and extended Ni-kshay Mitra to the patients' families [12].

• Charity cannot carry the main load

• Ni-kshay Mitra depends on donors who volunteer to 'adopt' patients.
• The Parliamentary Standing Committee on Health said this model 'cannot be considered as the mainstay' for ending TB. It also warned of complacency in the Ministry [13].

• Volunteer support goes where donors choose to give. The poorest districts may get the least.

• What should follow

• MoHFW should pay for nutrition support to families from a fixed budget line, as it already does for patients. The RATIONS result shows families are where new cases come from [10].
• When donor money is short, food is a low-cost way to prevent cases. It does not need new labs or new drugs [11].

11. Why Donor Cuts Still Matter to Self-Funded India

• The strongest argument against worrying
• India pays for most of its own TB response. BRICS as a group was 96% domestically funded in 2024 [3].
• So the 14% donor cut looks like someone else's problem.

• This is partly right. The direct hit to India's TB budget is small, and India's progress (a 21% fall in incidence, 2015–2024) came mainly from its own programme [5].

• Answer 1: new tools are bought with global money

• TB research gets $1.2 bn a year against a target of $5 bn [1].
• New vaccines, shorter treatments and quick tests are developed with pooled global money. India cannot easily build them alone.

• India has the most to gain from these tools, because South-East Asia has 35% of the world's new cases [1].

• Answer 2: India's own target has passed

• Incidence (new cases each year per lakh people) was still 187 per lakh in 2024 [5].

• The 2025 elimination date has passed with the disease far from gone. India still needs better tools, not just more of the same spending.

• Answer 3: the disease does not stop at the border

• Weak programmes in donor-dependent neighbours can mean more cases going undetected and untreated across the region.
• WHO's call to the South-East Asia Region to speed up action reflects this regional link [1].

12. Anchors for Answers

• Data: Domestic plus donor TB money in LMICs (~$6.6 bn) covers only about 30% of the $22 bn/yr needed for the UNHLM 2027 targets [1]
• Data: 82% of drug-resistant TB families face catastrophic costs (above 20% of household income), pooled across 31 countries [9]
• Data: RATIONS trial (ICMR, Jharkhand): food rations cut TB among patients' families by nearly half [10]
• Report/Committee: Parliamentary Standing Committee on Health (2023): the Ni-kshay Mitra adoption model 'cannot be considered as the mainstay' for ending TB [13]
• Comparison: Brazil, China and Russia pay 100% of their TB costs, while poorer non-BRICS LMICs still depend on donors for a large part of theirs [3]
• Scheme: Ni-kshay Poshan Yojana: ₹1,000/month by DBT from Oct 2024, plus ₹1,040 crore extra; nutrition support for families is the next step [12]

13. Mains Relevance

• GS-II: Issues relating to the development and management of the social sector and services relating to Health; important international institutions (WHO, Global Fund) and their mandates.
• GS-III: Science & Technology (R&D funding gaps for vaccines and diagnostics); mobilisation of resources.
• GS-IV (case study angle): Equity and the ethics of global health financing.
• Question stems: 1. "Shrinking international donor funding has turned TB elimination into a test of domestic political commitment." Discuss with reference to the WHO Global TB Report 2026 and India's TB Mukt Bharat drive. (15 marks) 2. Underinvestment in TB research and innovation keeps the world reliant on century-old tools. Examine the gaps and suggest how India can lead South-South collaboration. (10 marks) 3. Evaluate how well global health financing architectures such as the Global Fund hold up in an era of donor fatigue. What lessons does this hold for India's health diplomacy? (15 marks)

14. Related Topics to Study Next

• National TB Elimination Programme (NTEP) / Pradhan Mantri TB Mukt Bharat Abhiyaan: India's domestic response that the report's financing data reflect.
• Ni-kshay Poshan Yojana & Ni-kshay Mitra: nutrition support for patients; poverty and undernutrition drive TB.
• Global Fund to Fight AIDS, TB and Malaria: the main multilateral TB donor, whose 2024–26 cycle was cut [3].
• UN High-Level Meetings on TB (2018, 2023): where the 2027 targets and the $22 bn need come from [1].
• WHO End TB Strategy & SDG 3.3: the long-term targets the funding is measured against.
• Drug-resistant TB (MDR/XDR) and the BPaLM regimen: the treatment-innovation side of the research funding gap.
• TB vaccines (BCG, M72/AS01E candidates): the most visible casualties of the R&D shortfall.
• Universal Health Coverage & Ayushman Bharat: domestic financing as the route to sustainable disease programmes.

15. NCERT Concepts to Revise

• Global Tuberculosis Report (Economy): The article is about this WHO report; knowing what it tracks and how editions differ helps exam facts.
• Tuberculosis (Economy): Basic disease background: causes, risk factors like undernutrition, and India's large share of world cases.
• National TB Elimination Programme (Economy): India's domestic TB programme, whose spending and results the report's financing data reflect.
• WHO End TB Strategy (Economy): The long-term global targets that the funding gap is measured against.
• BRICS (Economy): BRICS countries supply 65% of domestic TB funding in low- and middle-income countries.
• Incidence (Economy): India's fall in TB incidence per lakh is a key statistic and often confused with deaths.
• Sustainable Development Goal 3 (Economy): SDG 3.3 sets the 2030 goal of ending the TB epidemic.
• World Health Organization (Polity): WHO publishes the report and sets global health norms and targets.
• Ni-kshay Poshan Yojana (Economy): Nutrition cash support for TB patients, tackling the undernutrition that drives TB.
• Ni-kshay Mitra (Economy): Community adoption of TB patients, part of India's TB Mukt Bharat drive.
• BPaLM regimen (Economy): Shorter drug-resistant TB treatment, an example of the innovation that research funding gaps slow.
• Global South (Polity): India could lead health cooperation among developing countries as donor funding shrinks.
• Universal health coverage (Economy): Domestic financing of disease programmes ties into the goal of affordable health care for all.
• Health expenditure (Economy): Explains public spending on health, central to the shift to domestic TB funding.
• Fiscal federalism (Economy): Health is a State subject, so Centre-State financing shapes TB response.

16. Common Errors / Trap Areas

• Report year vs data year: The 2026 report gives 2025 funding data. The 2025 report gave 2024 burden data (10.7 mn cases). Don't mix them up [1][2].
• "86% domestic" vs "96% domestic": 86% is the share of TB spending in 2025 (2026 report). 96% was the BRICS-specific domestic share in 2024 (2025 report) [1][3].
• Target year: The 2023 UNHLM targets are for 2027. The SDG target is 2030, and India's own elimination target was 2025 [1].
• Research target: It is $5 bn/yr for research & innovation, which is separate from the $22 bn/yr for prevention, diagnosis, treatment and care [1].
• WHO regions: India is in the WHO South-East Asia Region (SEARO), not the Western Pacific Region. The 35% figure refers to the new-case share of SEAR [1].